Previous Close | 5.57 |
Open | 5.52 |
Bid | 5.74 x 1800 |
Ask | 5.75 x 1400 |
Day's Range | 5.47 - 5.85 |
52 Week Range | 5.30 - 18.55 |
Volume | |
Avg. Volume | 8,625,622 |
Market Cap | 683.063M |
Beta (5Y Monthly) | 1.56 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -6.23 |
Earnings Date | Feb 26, 2024 - Mar 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 19.60 |
Subscribe to Yahoo Finance Plus to view Fair Value for NVAX
Biotech company Novavax (NASDAQ: NVAX) went from being relatively unknown just four years ago to becoming one of the U.S. COVID-19 vaccine market leaders. The company has faced many trials and tribulations in this period, however. If Novavax can mount a comeback, now may be as good a time as any to press the buy button while its shares are changing hands for just about $5.46 apiece.
Market performance hangs on U.S. vaccination rates for these three companies.
Following this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states.